Clinical Trial Update: Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of ACTIQ for managing breakthrough pain in cancer patients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Actiq (fentanyl)

Snippet

Sponsor: Cephalon | Conditions: Breakthrough Pain | Phase 3 | Status: COMPLETED